New inhaled therapy aims to slow lung transplant rejection
NCT ID NCT06018766
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an inhaled drug called LAM-001 in 30 lung transplant patients who have developed chronic rejection (BOS). Participants will inhale LAM-001 or a placebo daily for 48 weeks. The goal is to see if the drug is safe and can slow the decline in lung function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new scans catch lung transplant failure before It's too late?
- Can muscle strength predict lung transplant recovery?
- Blood markers may flag lung transplant danger — study investigates
- Your genes may hold the key to safer lung transplants
- Blood test clues could make antifungal dosing safer for transplant patients
- AI model could predict who needs a lung transplant for rare emphysema